Owners
Norgine is a Dutch pharmaceutical company that develops, manufactures and markets pharmaceutical products for the treatment of gastrointestinal disorders. The company has many years of experience in developing, acquiring and licensing assets. The Dutch company's portfolio includes more than 40 products, such as Movicol, Moviprep and Plenvu, used to treat gastrointestinal diseases.
History
2022: Goldman Sachs bought Norgine
On May 26, 2022, it became known that the Goldman Sachs Group investment division of Goldman Sachs Asset Management agreed to acquire a controlling stake in the pharmaceutical company Norgine BV from its founders.
The financial terms of the deal were not disclosed. According to Bloomberg, we can talk about the amount of about $2 billion.
 | We have been following Norgine for years and see great potential to grow the platform through organic initiatives as well as innovative licensing as well as M&A, "Goldman Sachs Asset Management, head of private equity in Europe, the Middle East and Africa, said in a statement. |  |
The U.S. bank's buyback unit bypassed at least two other private equity firms in the auction process to buy Norgine, asking not to be named in connection with confidential information, company officials said. The Stein family will remain the owner of a significant stake in the company.
As part of the asset sale, Norgine was advised by Moelis & Co., Rothschild & Co. and Jamieson Corporate Finance, while GSAM worked with Goldman Sachs' own investment bank and Goldman[1] Financial Group[2]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |